golimumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
golimumab

GtoPdb Ligand ID: 6776

Synonyms: CNTO-148 | CNTO148 | Simponi®

golimumab is an approved drug (FDA (2009), EMA (2009))

Compound class: Antibody

Comment: TNFα inhibitor.

Biosimilars:

Name	Trade name	Company	Approval	Indications
biosimilar golimumab; AVT05	Gobivaz®	Alvotech/Advanz Pharma	EMA (2025)	Biosimilar to Simponi®
biosimilar golimumab; BAT2506	Gotenfia®	Stada Arzneimittel	EMA (2026)	Biosimilar to Simponi®

View more information in the IUPHAR Pharmacology Education Project: golimumab

No information available.

No information available.

Summary of Clinical Use
Used in adults with various inflammatory conditions [3] e.g. moderate to severe active rheumatoid arthritis [1], active psoriatic arthritis, active ankylosing spondylitis and moderate to severe ulcerative colitis.

Summary of Clinical Use

Used in adults with various inflammatory conditions [3] e.g. moderate to severe active rheumatoid arthritis [1], active psoriatic arthritis, active ankylosing spondylitis and moderate to severe ulcerative colitis.

Mechanism Of Action and Pharmacodynamic Effects
Anti-TNFα monoclonal antibody which binds and neutralises soluble and membrane human TNFα, a pro-inflammatory cytokine associated with chronic inflammation.

Mechanism Of Action and Pharmacodynamic Effects

Anti-TNFα monoclonal antibody which binds and neutralises soluble and membrane human TNFα, a pro-inflammatory cytokine associated with chronic inflammation.

External links
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)